According to a new market report published by Persistence Market Research “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020”, the global biological drugs market was valued at US$ 161,056.5 Mn in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach US$ 287,139.7 Mn by 2020. Biological drugs are typically derived from living cells and are used in the prevention and treatment of various diseases such as cancer, blood disorders, auto-immune diseases, and other medical disorders. Biological drugs have more complex structures compared to that of conventional drugs. Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/2883 Some of the major players in the biological drugs market: Pfizer Inc. Abbott Laboratories. Novartis AG. Eli Lilly and Company. GlaxoSmithKline plc. Bristol-Myers Squibb Company. Merck & Co., Inc. Amgen Inc. Baxter International Inc. Biogen Idec. Request for Methodology@ https://www.persistencemarketresearch.com/methodology/2883 Globally, the biological drugs market is witnessing significant growth due to the increasing prevalence of chronic diseases and growing geriatric population. In addition, health and awareness initiatives by various government associations are also supporting the growth of the biological drugs market. However, high costs of biological drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, risks of adverse effects associated with biologic injectable drugs also inhibit the growth of the market. The global biological drugs market is anticipated to grow from an estimated US$ 161,056.5 Mn in 2014 to US$ 287,139.7 Mn by 2020 at a CAGR 10.1% during the forecast period. North America dominates the global biological drugs market. This is due to increasing use of biological drugs in the treatment of diseases such as cancer, diabetes, and other chronic diseases in the region. In addition, several clinics in the region are focusing on biological drugs for the treatment of various diseases. If You Want To Know The Business Opportunity/Market Value, Purchase The Premium Insight @ https://www.persistencemarketresearch.com/checkout/2883 The biological drugs market in Europe is growing due to increasing aging population in the region. For instance, according to a UN report, elderly people accounted for 23.2% of the total population in Germany in 2000, and the number is expected to reach 33.2% by 2025. Aging can lead to certain disorders such as age-related macular degeneration and glaucoma, which require effective biological drugs for their treatment. Low manufacturing costs in Asia are attracting biopharmaceutical companies to invest in the region, supporting the growth of the biological drugs market. Moreover, governments of some Asian countries are also supporting the growth of the biological drugs market by providing funds to life sciences research institutes and biotech companies for the construction of R&D and manufacturing facilities. About Us :- Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein. Contact us: Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected] Website – https://www.persistencemarketresearch.com
Biopharmaceutical Market Report by Size, Status and Forecast 2014-2020
According to IMARC Group latest report titled” Global Biopharmaceutical Market Report and Forecast 2021-2026”, the market is currently witnessing strong growth.
The global Biopharmaceutical Market to exhibit moderate growth during the next five years.
They mainly include monoclonal antibodies, recombinant growth factors, purified proteins, recombinant hormones, vaccines, synthetic immunomodulators, etc., utilized for therapeutic or in vivo diagnostic purposes.
Biopharmaceuticals find extensive applications pertaining to autoimmune disorders, inflammatory and infectious diseases, hormonal disorders, cardiovascular ailments, metabolic disorders, neurological diseases, etc.Get a sample copy of this Report: https://www.imarcgroup.com/biotechnology-industry/requestsampleAs the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.The expanding geriatric population, along with the rising prevalence of chronic diseases, is primarily driving the biopharmaceutical market across the globe.
Moreover, their ability to attack targets beyond the reach of traditional small molecule drugs is further contributing to the adoption of these biologics in the treatment of various life-threatening diseases.
Besides this, the rising need to alleviate the side effects of various small-molecule therapeutics and invasive surgical treatments will continue to drive the market growth over the forecast period.View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biotechnology-industryCompetitive Landscape with Key players:The global biopharmaceutical market is concentrated in nature with the presence of a small number of key players who compete in terms of prices and quality.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
Biopharmaceutical Logistic is the logistics of Biopharmaceutical, medical and surgical supplies, and other products needed to support doctors, nurses, and other health and dental care providers.
Because it’s final customers are responsible for the lives and health of their patients, medical logistics is unique in that it seeks to optimize effectiveness rather than efficiency.
According to this study, over the next five years the Biopharmaceutical Logistic market will register a 4.0% CAGR in terms of revenue, the global market size will reach US$ 89900 million by 2024, from US$ 71000 million in 2019.
In particular, this report presents the global market share (sales and revenue) of key companies in Biopharmaceutical Logistic business, shared in Chapter 3.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-biopharmaceutical-logistic-2019-2024-23The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.The key manufacturers covered in this report: Breakdown data in in Chapter 3.Deutsche Post DHLKuehne + NagelFedExAmerisourceBergenUPS (Marken)DB SchenkerXPO LogisticsPanalpinaNippon ExpressGEODISVersaColdAgilityDSVSinotransKerry LogisticsSF ExpressCEVACH RobinsonAir Canada CargoThis report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceutical Logistic market by product type, application, key manufacturers and key regions and countries.This study considers the Biopharmaceutical Logistic value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.Cold Chain LogisticsNon-cold Chain LogisticsSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Ground ShippingSea ShippingAir ShippingThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesIn addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole.
It also analyzes key emerging trends and their impact on present and future development.Research objectivesTo study and analyze the global Biopharmaceutical Logistic consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Biopharmaceutical Logistic market by identifying its various subsegments.Focuses on the key global Biopharmaceutical Logistic manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Biopharmaceutical Logistic with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Biopharmaceutical Logistic submarkets, with respect to key regions (along with their respective key countries).Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-biopharmaceutical-logistic-2019-2024-23Table of content2019–2024 Global Biopharmaceutical Logistic Consumption Market Report1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered2 Executive Summary2.1 World Market Overview2.1.1 Global Biopharmaceutical Logistic Consumption 2014–20242.1.2 Biopharmaceutical Logistic Consumption CAGR by Region2.2 Biopharmaceutical Logistic Segment by Type2.2.1 Cold Chain Logistics2.2.2 Non-cold Chain Logistics2.3 Biopharmaceutical Logistic Consumption by Type2.3.1 Global Biopharmaceutical Logistic Consumption Market Share by Type (2014–2019)2.3.2 Global Biopharmaceutical Logistic Revenue and Market Share by Type (2014–2019)2.3.3 Global Biopharmaceutical Logistic Sale Price by Type (2014–2019)2.4 Biopharmaceutical Logistic Segment by Application2.4.1 Ground Shipping2.4.2 Sea Shipping2.4.3 Air Shipping2.5 Biopharmaceutical Logistic Consumption by Application2.5.1 Global Biopharmaceutical Logistic Consumption Market Share by Application (2014–2019)2.5.2 Global Biopharmaceutical Logistic Value and Market Share by Application (2014–2019)2.5.3 Global Biopharmaceutical Logistic Sale Price by Application (2014–2019)CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
Recently published a report entitled Biopharmaceutical Excipients Market projected till 2026, added by Value Market Research, covers key players along with their market share and strategic development adopted by them.
Further, the report provides market size, share, trends, outlook and forecast based on historical data coupled with drivers, restraints, and opportunities.The broad biopharmaceutical excipients market has been sub-grouped into chemistry, functionality, and application.
The report studies these subsets with respect to the geographical segmentation.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
This detail will lead to a focused approach leading to identification of better opportunities.Request a FREE Sample Copy of Biopharmaceutical Excipients Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/biopharmaceutical-excipients-market/download-sampleBy ChemistryPlantsAnimalsMineralsSynthetic SourcesBy FunctionalityBindersDiluentsGlidentDisintegrantsOthersBy ApplicationOralParenteralTopicalOthersThe report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the biopharmaceutical excipients market include Ashland Inc., BASF SE, Croda International Plc, Evonik Industries AG, FMC Corporation, Innophos Holdings Inc., MEGGLE Group Wasserburg BG Excipients & Technology, Roquette Group, The Dow Chemical Company, and The Lubrizol Corporation.
Electric Vehicle Batteries Market:WiseGuyReports.com adds “Global Electric Vehicle Batteries Market Size, Status and Forecast 2020-2030” reports to its database.Executive SummaryThe global electric vehicles batteries market is expected decline from $23.17 billion in 2019 to $22.24 billion in 2020 at a compound annual growth rate (CAGR) of -6.17%.
The market is then expected to recover and reach $35.36 billion in 2023 at CAGR of 16.71%.The electric vehicles batteries market consists of sales of electric vehicles batteries.
Electric vehicles batteries are used to power the electronic vehicles and are rechargeable in nature.
These batteries support the clean energy initiative as they don’t emit any harmful gases which causes damage to the environment.Asia Pacific was the largest market in the electric vehicles batteries market in 2019.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5357996-electric-vehicle-batteries-global-market-report-2020-30The charging of Electric vehicle batteries using Vehicle to grid technology is expected to gain traction in EV batteries Market.
Vehicle to grid technology is a Bi-directional charging system technology in which plug-in electric vehicles like battery electric vehicles (BEV), plug-in hybrids (PHEV) or hydrogen fuel cell electric vehicles (FCEV) batteries’ can communicate with the power grid for either returning electricity to the grid, to homes during the peak times or increase their charging rate to discharge and charge the battery accordingly.
The new vehicle released by the Nissan along with ENEL X the Nissan leaf in October 2017 in Japan for the model year 2018 uses Vehicle to grid Technology which can be used to power the home during times of need or push back energy to the grid that is to sell the electricity to the gird.
According to IMARC Group latest report titled” Global Biopharmaceutical Market Report and Forecast 2021-2026”, the market is currently witnessing strong growth.
The global Biopharmaceutical Market to exhibit moderate growth during the next five years.
They mainly include monoclonal antibodies, recombinant growth factors, purified proteins, recombinant hormones, vaccines, synthetic immunomodulators, etc., utilized for therapeutic or in vivo diagnostic purposes.
Biopharmaceuticals find extensive applications pertaining to autoimmune disorders, inflammatory and infectious diseases, hormonal disorders, cardiovascular ailments, metabolic disorders, neurological diseases, etc.Get a sample copy of this Report: https://www.imarcgroup.com/biotechnology-industry/requestsampleAs the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.The expanding geriatric population, along with the rising prevalence of chronic diseases, is primarily driving the biopharmaceutical market across the globe.
Moreover, their ability to attack targets beyond the reach of traditional small molecule drugs is further contributing to the adoption of these biologics in the treatment of various life-threatening diseases.
Besides this, the rising need to alleviate the side effects of various small-molecule therapeutics and invasive surgical treatments will continue to drive the market growth over the forecast period.View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biotechnology-industryCompetitive Landscape with Key players:The global biopharmaceutical market is concentrated in nature with the presence of a small number of key players who compete in terms of prices and quality.
Biopharmaceutical Logistic is the logistics of Biopharmaceutical, medical and surgical supplies, and other products needed to support doctors, nurses, and other health and dental care providers.
Because it’s final customers are responsible for the lives and health of their patients, medical logistics is unique in that it seeks to optimize effectiveness rather than efficiency.
According to this study, over the next five years the Biopharmaceutical Logistic market will register a 4.0% CAGR in terms of revenue, the global market size will reach US$ 89900 million by 2024, from US$ 71000 million in 2019.
In particular, this report presents the global market share (sales and revenue) of key companies in Biopharmaceutical Logistic business, shared in Chapter 3.Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-biopharmaceutical-logistic-2019-2024-23The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.The key manufacturers covered in this report: Breakdown data in in Chapter 3.Deutsche Post DHLKuehne + NagelFedExAmerisourceBergenUPS (Marken)DB SchenkerXPO LogisticsPanalpinaNippon ExpressGEODISVersaColdAgilityDSVSinotransKerry LogisticsSF ExpressCEVACH RobinsonAir Canada CargoThis report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceutical Logistic market by product type, application, key manufacturers and key regions and countries.This study considers the Biopharmaceutical Logistic value and volume generated from the sales of the following segments:Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.Cold Chain LogisticsNon-cold Chain LogisticsSegmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.Ground ShippingSea ShippingAir ShippingThis report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaSpainMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC CountriesIn addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole.
It also analyzes key emerging trends and their impact on present and future development.Research objectivesTo study and analyze the global Biopharmaceutical Logistic consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.To understand the structure of Biopharmaceutical Logistic market by identifying its various subsegments.Focuses on the key global Biopharmaceutical Logistic manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.To analyze the Biopharmaceutical Logistic with respect to individual growth trends, future prospects, and their contribution to the total market.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).To project the consumption of Biopharmaceutical Logistic submarkets, with respect to key regions (along with their respective key countries).Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-biopharmaceutical-logistic-2019-2024-23Table of content2019–2024 Global Biopharmaceutical Logistic Consumption Market Report1 Scope of the Report1.1 Market Introduction1.2 Research Objectives1.3 Years Considered1.4 Market Research Methodology1.5 Economic Indicators1.6 Currency Considered2 Executive Summary2.1 World Market Overview2.1.1 Global Biopharmaceutical Logistic Consumption 2014–20242.1.2 Biopharmaceutical Logistic Consumption CAGR by Region2.2 Biopharmaceutical Logistic Segment by Type2.2.1 Cold Chain Logistics2.2.2 Non-cold Chain Logistics2.3 Biopharmaceutical Logistic Consumption by Type2.3.1 Global Biopharmaceutical Logistic Consumption Market Share by Type (2014–2019)2.3.2 Global Biopharmaceutical Logistic Revenue and Market Share by Type (2014–2019)2.3.3 Global Biopharmaceutical Logistic Sale Price by Type (2014–2019)2.4 Biopharmaceutical Logistic Segment by Application2.4.1 Ground Shipping2.4.2 Sea Shipping2.4.3 Air Shipping2.5 Biopharmaceutical Logistic Consumption by Application2.5.1 Global Biopharmaceutical Logistic Consumption Market Share by Application (2014–2019)2.5.2 Global Biopharmaceutical Logistic Value and Market Share by Application (2014–2019)2.5.3 Global Biopharmaceutical Logistic Sale Price by Application (2014–2019)CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
Recently published a report entitled Biopharmaceutical Excipients Market projected till 2026, added by Value Market Research, covers key players along with their market share and strategic development adopted by them.
Further, the report provides market size, share, trends, outlook and forecast based on historical data coupled with drivers, restraints, and opportunities.The broad biopharmaceutical excipients market has been sub-grouped into chemistry, functionality, and application.
The report studies these subsets with respect to the geographical segmentation.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
This detail will lead to a focused approach leading to identification of better opportunities.Request a FREE Sample Copy of Biopharmaceutical Excipients Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/biopharmaceutical-excipients-market/download-sampleBy ChemistryPlantsAnimalsMineralsSynthetic SourcesBy FunctionalityBindersDiluentsGlidentDisintegrantsOthersBy ApplicationOralParenteralTopicalOthersThe report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the biopharmaceutical excipients market include Ashland Inc., BASF SE, Croda International Plc, Evonik Industries AG, FMC Corporation, Innophos Holdings Inc., MEGGLE Group Wasserburg BG Excipients & Technology, Roquette Group, The Dow Chemical Company, and The Lubrizol Corporation.
Electric Vehicle Batteries Market:WiseGuyReports.com adds “Global Electric Vehicle Batteries Market Size, Status and Forecast 2020-2030” reports to its database.Executive SummaryThe global electric vehicles batteries market is expected decline from $23.17 billion in 2019 to $22.24 billion in 2020 at a compound annual growth rate (CAGR) of -6.17%.
The market is then expected to recover and reach $35.36 billion in 2023 at CAGR of 16.71%.The electric vehicles batteries market consists of sales of electric vehicles batteries.
Electric vehicles batteries are used to power the electronic vehicles and are rechargeable in nature.
These batteries support the clean energy initiative as they don’t emit any harmful gases which causes damage to the environment.Asia Pacific was the largest market in the electric vehicles batteries market in 2019.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5357996-electric-vehicle-batteries-global-market-report-2020-30The charging of Electric vehicle batteries using Vehicle to grid technology is expected to gain traction in EV batteries Market.
Vehicle to grid technology is a Bi-directional charging system technology in which plug-in electric vehicles like battery electric vehicles (BEV), plug-in hybrids (PHEV) or hydrogen fuel cell electric vehicles (FCEV) batteries’ can communicate with the power grid for either returning electricity to the grid, to homes during the peak times or increase their charging rate to discharge and charge the battery accordingly.
The new vehicle released by the Nissan along with ENEL X the Nissan leaf in October 2017 in Japan for the model year 2018 uses Vehicle to grid Technology which can be used to power the home during times of need or push back energy to the grid that is to sell the electricity to the gird.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.